Roivant says closely watched immune drug succeeded in new eye disease: The two positive trials could tee up the drug, called Lisraya and approved in a skin ...
statnews.com/2026/10/21/roivant-immune-drug-lisraya-noninfectious-uveitis-trial-results/
Roivant says closely watched immune drug succeeded in new eye disease
Matt Gline, CEO of Roivant, tells the #STATSummit audience he’s “rooting for” Anthropic’s foray into biotech. But he also has a few words of advice for Dario Amodei: ... Show more
Ramaswamy promoted a failed Alzheimer’s drug. Did he knowingly profit from it?: Amy Acton’s campaign says Vivek Ramaswamy promoted an Alzheimer’s drug he knew ...
politifact.com/factchecks/2026/oct/12/amy-acton/ramaswamy-alzheimers-drug-intepirdine-ohio/
Ramaswamy promoted a failed Alzheimer’s drug. Did he knowingly profit from ...
Ramaswamy’s Ohio Homecoming Likely Shaved Eight Figures Off His Tax Bill: The billionaire gubernatorial candidate says lower taxes will make founders flock to ...
forbes.com/sites/johnhyatt/2026/10/02/how-vivek-ramaswamys-well-timed-ohio-move-likely-saved-him-12-million-in-taxes/
Ramaswamy’s Ohio Homecoming Likely Shaved Eight Figures Off His Tax Bill
Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
statnews.com/2026/09/10/roivant-biotech-dealmaking-mosliciguat-origins/
Roivant is one of the savviest dealmakers in biotech. It also has a secret ...
FDA approves AstraZeneca breast cancer drug: Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs ...
statnews.com/2026/09/08/biotech-news-fda-approves-astrazeneca-breast-cancer-drug/
FDA approves AstraZeneca breast cancer drug
Roivant lung disease drug hits mid-stage study goals: Roivant reports its experimental drug mosliciguat for a type of pulmonary hypertension achieved goals of ...
statnews.com/2026/09/08/roivant-mosliciguat-pulmonary-hypertension-interstitial-lung-disease-results/
Roivant lung disease drug hits mid-stage study goals
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
statnews.com/2026/08/28/biotech-news-astrazeneca-ionis-detail-surprise-failure-of-heart-disease-drug/
AstraZeneca and Ionis detail surprise failure of heart disease drug ...
FDA approves Roivant therapy for rare autoimmune disease: The drug, Lisraya, provides a new option for patients with dermatomyositis — and a new kind of ...
statnews.com/2026/08/27/fda-approves-roivant-therapy-for-rare-autoimmune-disease/
FDA approves Roivant therapy for rare autoimmune disease
Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement, FDA warning letters, and more
statnews.com/pharmalot/2026/03/04/moderna-patents-fda-affordability-charities-novo-telehealth/
Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement ...
Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines
statnews.com/2026/03/03/moderna-settles-covid-vaccine-suit-roivant/
Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind ...
The biotech founder and anti-woke activist spent millions on his unsuccessful campaign, yet he is wealthier now than when he entered the race 11 months ago ... Show more

trib.al/aUzhCzD
Key FactsRamaswamy Backs Trump at New Hampshire Rally
Jan 17, 2024 · Reading time: ~45 sec.
Summary created with AI assistance · Source: newsweek.com
  • Ramaswamy described the situation as a historic moment like 1776 and called for leadership to achieve victory.

  • He urged Nikki Haley and Ron DeSantis to leave the race and support Trump.

  • Trump won the Iowa caucuses with 51 percent, ahead of DeSantis (21.2), Haley (19.1), and Ramaswamy (7.7).

  • After Ramaswamy’s speech, the former rivals embraced; Trump said Ramaswamy would work with him long term.
  • Right now, we need a commander-in-chief who will lead us to victory in this war. This is a 1776 moment right now.
    — Vivek Ramaswamy during a New Hampshire endorsement speech for Donald Trump
Vivek Ramaswamy sells $33 million in Roivant stock to boost campaign: Ramaswamy plans to make a "significant investment" in his campaign ...
axios.com/2024/01/04/vivek-ramaswamy-sells-33-million-roivant-stock-campaign
Vivek Ramaswamy sells $33 million in Roivant stock to boost campaign